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There is a general perception that patients with polycystic
kidney disease on peritoneal dialysis have poor long-term
technique survival. In order to test this opinion, we
performed a retrospective analysis comparing results of
56 consecutive patients with polycystic kidney disease to
56 non-diabetic patients with bilateral small kidneys. The
patient groups were all initiated on peritoneal dialysis over a
12 year period and matched for age, gender and years of end
stage renal failure. After a mean follow-up period of 37
months the two groups were statistically indistinguishable in
terms of mortality, kidney transplantation-censored
technique survival, median death-censored technique
survival, the number of patients switched permanently to
hemodialysis due to technique failure and the rate of
peritonitis. On Cox regression (multivariate) analysis, only the
baseline serum albumin level was a significant and
independent risk factor of death-censored technique failure.
Our study found no difference in long term outcome of
peritoneal dialysis therapy in patients with polycystic kidney
disease compared to a non-diabetic matched control group.
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Autosomal dominant polycystic kidney disease (PKD) is the
fourth leading cause of end-stage renal failure (ESRF) and
accounts for approximately 3–10% of all patients being
treated for ESRF in the Western world.1 It is assumed that
PKD patients on peritoneal dialysis (PD) have poor long-
term technique survival because of various renal and
nonrenal aspects of PKD, including enlarged kidneys,
abdominal wall complications,2 leaks,3,4 and intestinal
perforation.5 However, there has been no formal analysis of
this assumption. The only other study6 aimed to evaluate the
efficacy of PD in patients with PKD reported no specific
problems related to PKD. However, it consisted of few PKD
patients, an ill-defined control group and a short follow-up
period. Hence, till date, outcome of PD in PKD patients
remains unclear. Due to virtual absence of data on long-term
outcome of PD in PKD patients, we undertook a retro-
spective cohort study to compare long-term rates of PD
survival in 56 consecutive PKD patients commenced de novo
on PD with age, sex, and year of commencement of PD
matched nondiabetic patients with bilateral small kidneys.
RESULTS
Study patient characteristics
Between 1 January 1994 and 31 December 2005, a total of 75
patients underwent on renal replacement therapy for ESRF
secondary to PKD at our centre (Figure 1). Out of 75
patients, 56 were initiated on PD (group B) and 19 on
hemodialysis (HD, group A). Each PKD patient starting PD
was matched in accordance to our protocol (nondiabetic
patients with bilateral small kidneys matched for age, sex, and
year of ESRF); group C (Figure 1).
The baseline characteristics of group B and C patients are
shown in Table 1. There were no statistically significant
differences in relevant biochemical investigations, mean
duration on PD, and Davies comorbidity score. Estimated
glomerular filtration rate at the beginning of PD therapy in
the PKD group (6.1±1.4 ml/min per 1.73 m2) was similar to
the control group (6.02±1.7 ml/min per 1.73 m2). No
differences were noted among the baseline assessment of
dialysis clearance, residual renal function, and membrane
function between the two groups including Kt/V, weekly
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endogenous and dialysis creatinine clearance, residual urine
output, daily ultrafiltration volume, and dialysate/plasma
creatinine (D/Pcr) ratio (Table 2). Dialysate inflow and
outflow times measured during peritoneal equilibrium test
(PET) were similar too, including residual dialysate volume.
PD technique survival
The outcome of patients is shown in Figure 1 and Table 3. By
the end of the study, seven patients (12.5%) died in the PKD
group on PD, two patients (10.5%) died in the PKD group
on HD, and five patients (9%) died in the control group. Out
of seven deaths in the PKD on PD, two were due to
aneurysmal intracerebral bleed. In all, 17 (30%) PKD patients
ESRF secondary to PKD 
(1 Jan 1994 to 31 Dec 2005)
N=75
Commenced de novo onto: 
Group C 
Matched case control 
N=56
Group B 
PD 
N=56
 Group A 
HD
N=19
Death 5 7 2
TP 21 22 8
Transferred to HD 14 17
Peritonitis rate 
(per 100 patient-months)
3.7 3.6 NA
NA
Figure 1 | Consort diagram showing the outcome of PKD and control patients.
Table 1 | Demographics and biochemical characteristics of
PKD and control patients at the beginning of PD therapy
PKD (n=56) Controls (n=56) P
Age (years) 50.8±11.6 50.3±11.5 NS
Gender
Male 25 (45%) 25 (45%) NS
Female 31 (55%) 31 (55%)
Ethnicity
Caucasians 44 (80%) 34 (62%) NS
Asians 6 (11%) 14 (25%) NS
Afro-Carribeans 5 (9%) 7 (12%) NS
Year of ESRF
1994–1999 21 (37%) 21 (37%) NS
2000–2005 35 (63%) 35 (63%) NS
Late presenters 0% 0% NS
Duration of PD (months) 36.6±23.3 38.7±21.9 NS
Body surface area 1.80±0.28 1.78±0.24 NS
Davies comorbidity score
0 (low risk) 49 (87.5%) 49 (87.5%) NS
1–2 (medium risk) 7 (12.5%) 7 (12.5%)
X3 (high risk) 0 0
Hemoglobin (g/100 ml) 11.0±1.5 10.6±1.9 NS
Calcium (mmol/l) 2.4±0.3 2.3±0.2 NS
(mg/100 ml) 9.8±1.2 9.5±1.0
Phosphate (mmol/l) 1.9±0.5 1.90±0.5 NS
(mg/100 ml) 6.1±1.7 5.9±1.6
Albumin (mg/100 ml) 39.8±3.9 38.06±4.9 NS
(g/l) 3.9±0.3 3.8±0.4
Cholesterol (mmol/l) 4.5±1.1 4.46±1.05 NS
(mg/100 ml) 176±45 172±41
CRP (mg/l) 7.0±3.2 7.19±3.2 NS
eGFR (ml/min per 1.73 m2) 6.1±1.4 6.02±1.7 NS
CRP, C-reactive protein; EGFR, estimated glomerular filtration rate; ESRF, end-stage
renal failure; NS, not significant; PD, peritoneal dialysis; PKD, polycystic kidney
disease.
Values are mean±s.d.
Table 2 | Baseline dialysis adequacy and membrane function
of PKD and control patientsa
PKD
(n=53)b
Controls
(n=56) P
Kt/V 2.3±0.5 2.1±0.4 NS
Endogenous weekly creatinine
clearance (l per week 1.73 m2)
28.4±22.9 26.7±25.5 NS
Dialysis weekly creatinine clearance
(l per week 1.73 m2)
43.1±10.9 46.0±11.9 NS
Ultrafiltration (ml) 1045±676 1197±583 NS
Residual urine output (ml per 24 h) 729.3±675.1 654.5±583.7 NS
Transporter status
High average and high 26 (48%) 23 (40%) NS
Low average and low 30 (52%) 33 (60%) NS
D:P creatinine (4 h) 0.64±0.12 0.61±0.21 NS
Dialysate
Infusion time (min)c 10.2±2.2 10.6±1.9 NS
Drain time (min)c 15±3 16±5 NS
Residual dialysate volume (ml) 197±135 176±119 NS
On APD 11 (18.5%) 10 (17.8%) NS
APD, ambulatory peritoneal dialysis; D:P creatinine (4 h), dialysate-to-plasma ratios of
creatinine at 4 h; PKD, polycystic kidney disease.
Values are mean±s.d..
aPET was performed after a mean duration of 5.6 months in the PKD group (95% CI
3.94–7.37) versus 6.8 months in the control group (95% CI 4.46–9.1).
bThree patients had early leaks, therefore, baseline dialysis indices were available on
remaining 53 patients.
cDialysate infusion and outflow times were measured according to the Twardoski’s
PET test.
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(versus 14 (25%) in the control group) were permanently
transferred to hemodialysis because of technique failure.
On logrank test (Figure 2), there was no difference in the
technique survival censored for death and kidney transplan-
tation (hazard ratio, 1.4; 95% confidence interval (CI),
0.70–2.9; P¼ 0.32) with the median technique survival for
the PKD group being 7.0 years versus 6.4 years for the control
group (95% CI 0.50–1.59; P40.05). There was no difference
in the composite of technique and patient survival (logrank
test) between the two groups (Figure 3; P¼ 0.15). The
median survival for the composite of technique and patient
survival was 3.9 years (PKD group) versus 4.1 years (control
group) (95% CI 0.38–1.49).
The relative risk (RR) of PD technique failure was
determined using the Cox regression analysis (Table 4).
Univariate analysis revealed serum C-reactive protein (CRP)
and serum albumin levels measured on commencement of
PD as risk factors. On multivariate analysis (backward
conditional regression), only hypoalbuminemia (RR 0.86,
95% CI 0.74–0.95, Po0.05) at the start of PD therapy was
noted to be an independent risk factor for PD technique
failure censored for death and transplantation. The RR for
technique failure decreases by 14% for a 1 g/l increased serum
albumin. The causes of technique failure in PKD group
included peritonitis (eight patients), leaks (three patients; all
leaks were within 1 month of commencement of PD),
membrane failure (three patient), and irreducible umbilical
hernia (one patient), bilateral nephrectomy (one patient).
There was no difference in the proportion of patients who
underwent transplantation during the study duration in the
two groups (22 (39%) in PKD versus 21 (37%) in control
group).
Peritonitis
The overall peritonitis rates were similar in both the groups
(Table 5); one episode per 26 months in PKD patients versus
one episode per 31 months in the control. A total of 14 (25%)
and 12 (21%) patients underwent PD catheter removal, in
the PKD and control groups, respectively. There was no
difference between the survival curves for time to first or
(Figure 4; logrank test, P¼ 0.26) second peritonitis episodes
Table 3 | Outcome of 56 PKD patients and 56 control patients
PKD Control P
Deatha 7 (12%) 5 (9%) NS
Transplantation 22 (39%) 21 (37%) NS
Technique failure 17 (30%) 14 (25%) NS
Peritonitis 8 9
Leak 3 1
Membrane failure 3 2
Patient choice 1 2
Irreducible umbilicalb hernia 1 0
Bilateral nephrectomy 1 0
NS, not significant; PKD, polycystic kidney disease.
aTwo patients died of aneurysmal intracerebral bleed.
bFour patients required umblical hernia surgery repair; however, only one had
irreducible umbilical hernia, resulting in permanent cessation of PD.
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Figure 2 | Transplant and death-censored technique survival
in PKD patients and controls. Data were censored at the time
of kidney transplantation, death, or 31 December 2005 for
death-censored technique survival. Ticks represent censored
observations. Logrank P¼ 0.32 (not significant).
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Figure 3 | Composite of technique and patient survival
(transplant censored)* in PKD patients and controls. Ticks
represent censored observations. Logrank P¼ 0.15 (not
significant).
Table 4 | Factors associated with death-censored technique
failure in PKD patients on PD (Cox regression models)
Univariate Multivariate
Factors RR (95% CI) P RR (95% CI) P
Albumina (m 1 g/l) 0.84 (0.74–0.90) o0.05 0.86 (0.74–0.95) o0.05b
CRPa 1.18 (1.01–1.38) o0.05
Baseline eGFR 0.92 (0.58–1.46) 0.72
Baseline Kt/V 0.83 (0.19–3.49) 0.80
Baseline RRF
(l per week 1.73 m2)
0.99 (0.96–1.02) 0.73
D:P creatinine (4 h) 1.00 (0.99–1.00) 0.65
Residual urine output
(ml per 24 h)
1.00 (0.99–1.00) 0.46
95% CI, 95% confidence interval; CRP, C-reactive protein; D:P creatinine (4 h),
dialysate-to-plasma ratios of creatinine at 4 h; eGFR, endogenous glomerular
filtration rate; PD, peritoneal dialysis; PKD, polycystic kidney disease.; RR, relative risk.
aOn univariate analysis, serum albumin levels and serum CRP levels measured at the
beginning of PD therapy were significantly associated with death-censored
technique failure.
bOn multivariate analysis (backward conditional regression), only baseline serum
albumin was an independent risk factor of death-censored technique survival. The
lower the serum albumin levels at the start of PD therapy, the worse the outcome
with respect to technique failure.
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(Figure 5; logrank test, P¼ 0.48) in the PKD and control
groups. The median survival for the first peritonitis episode is
3.7 and 2.7 years (95% CI 0.82–1.91), for the control and
PKD groups, respectively.
In the PKD group, the organism identified to be Gram
positive in 21 (39%) cases (15 episodes of Staphylococcus
epidermidis, 3 of S. aureus, 2 of Streptococcus species, and 1 of
Enterococcus) and Gram-negative rods in 12 (22%) cases (five
episodes of Escherichia coli, one of Klebseilla, and six caused
by other rods). Three patients (5%) in the PKD group had
fungal peritonitis, whereas no organisms were identified in 18
episodes (34%).
In the control group, bacteria causing peritonitis were
identified to be Gram positive in 32 episodes (58%). (18
episodes of S. epidermidis, 9 of S. aureus, 4 of enterococci,
and 1 of Streptococcus species) and Gram negative in 12
(22%) episodes (two episodes of Klebseilla, two of E. coli, and
eight from other rods). Eleven peritonitis episodes (20%)
were culture negative, whereas none of the patients in this
group had fungal peritonitis.
DISCUSSION
To the best of our knowledge, this is the first study to
investigate the long-term outcome of PD in PKD patients.
Our findings demonstrate that patient survival, technique
survival, and peritonitis rates are similar in patients with
PKD on PD when compared to nondiabetic ESRF patients on
PD with bilateral small kidneys. According to this study, the
median death-censored technique survival for the PKD
group is 7.0 years. Our findings confirm the results of the
only other study6 aimed to determine the outcome of PD in
PKD patients. In line with our observation, Hadimeri et al.6
also observed similar technique survival for PKD patients
compared to the control group. However, it consisted of few
patients with a short follow-up duration and an ill-defined
control group.
In 1996, Pirson et al.7 reviewed their own experience and
pertinent literature on the outcome of renal replacement
therapy in PKD patients. However, only patients on HD and
renal transplantation were examined because no data were
available for PD therapy. Subsequently, anecdotal reports and
few case series have emphasized the association between PKD
and mechanical complications of PD such as leaks,3,4 and
abdominal wall hernias.2 It is, traditionally, believed that this
relationship is caused by increased intraabdominal pressure
due to the large volume of polycystic kidneys and render
patient with PKD at increased risk for technique failure. In
our study, four patients had early leaks, three in PKD group
(5.0%), and one in control group (1%). All four leaks
occurred within 1 week of commencement of PD. This
finding is similar to the findings by Fletcher et al.4 who
reported five cases of acute right-sided hydrothoraces
complicating PD, four of whom had PKD. However, late
leakage (15%) in PKD patients on PD has also been
reported.3 Another study2 identified PKD as a risk factor
associated with higher rate of hernias, though not for
leaks. In our study cohort, four PKD patients underwent
umbilical hernia surgery, in addition, to one developing
irreducible umbilical hernia leading to technique failure.
Though, till date, the published literature has highlighted the
Table 5 | Peritonitis during PD therapy in 56 PKD and 56
control patients
PKD Control P
Peritonitis rate 1 episode
per 26 months
1 episode
per 31 months
NS
Episodes requiring catheter 14 (25%) 12 (21%) NS
removal—no. of episodes (%)
Organisms—no. of episodes (%)
Gram positive—no. (%) 21 (39%) 32 (58%)
Staphylococcus aureus 3 9
Staphylococcus epidermidis 15 18
Streptococcus species 2 1
Enterococci 1 4
Gram negative—no. (%) 12 (22%) 12 (22%)
Klebsiella 1 2
Escherichia Coli 5 2
Other 6 8
Fungi—no. (%) 3 (5%) 0
No growth—no. (%) 18 (34%) 11 (20%)
95% CI, 95% confidence interval; NS, not significant; PKD, polycystic kidney disease.
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Figure 5 | Kaplan–Meier estimates of event (second peritonitis
episode*) free survival in PKD patients and controls.
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Figure 4 | Kaplan–Meier estimates of event (first peritonitis
episode*) free survival in PKD patients and controls.
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aforementioned uncommon complications; the key question
whether these associations translate into overall long-term
poor technique survival remained unanswered until the
findings of this study.
At our centre, bilateral nephrectomy is not a prerequisite
for PKD patients to go onto the transplant wait list. However,
our policy is to perform a nephrectomy if the polycystic
kidney is so large that the surgeons feel it will compromise
successful transplantation. As a rule of thumb, if on
computed tomography scan the lower limit of polycystic
kidney falls below the pelvic brim, our surgeons generally
recommend nephrectomy. Other reasons for which we
perform nephrectomy are recurrent cysts infections or other
complications from PKD. However, this translated into only
2 out of 75 patients (one in PD group and one in HD group)
requiring nephrectomy. If a PKD patient undergoes ne-
phrectomy, we do not attempt PD as we feel it is highly likely
that the peritoneum will be damaged.
It is widely believed that patients with PKD on PD are
susceptible to Gram-negative peritonitis because of its
association with colonic diverticulitis. Our analysis reveal
that incidence of peritonitis, including Gram-negative
peritonitis, is not increased in patients with PKD. However,
it should be noted that although we adhered to International
society for peritoneal dialysis guidelines for the collection
and culture methods, we had a high culture-negative rate.
Culture-negative peritonitis is likely to be caused by
fastidious Gram-positive organisms and despite the high
culture-negative rate, it is unlikely that the peritonitis from
Gram negative (originating from the bowel) is not signifi-
cantly higher in the PKD patients. Moreover, Gram-negative
organisms respond poorly to antibiotic therapy, but cure
with empiric antibiotic therapy was equal in the PKD and
control patients. Our finding is in agreement with other
studies,6,8 though both these studies evaluated peritonitis
events over a short follow-up period. There has also been
concern expressed that PD catheter flow rate may be
impaired because of the polycystic kidneys. During the
baseline PET assessment, we timed the inflow and outflow of
the dialysate and found no differences. Moreover, there was
no statistically difference in the residual dialysate volume
after the overnight dialysate was drained out during the PET.
Serum albumin is a well-known prognostic indicator of
overall mortality in ESRF patients on PD. Blake et al.9 showed
that initial, as distinct from ongoing, serum albumin is an
independent predictor of technique failure in patients on PD.
Our findings suggest that this is applicable to PKD patients
on PD as well. The RR of death-censored technique failure of
PD in patients with PKD increases by 14% for every 1 g/l
decrease of baseline serum albumin. This is independent of
age, baseline CRP level, estimated glomerular filtration rate at
the beginning of PD, Kt/V, residual urine output, ultrafiltra-
tion volume, and D:Pcr creatinine (4 h). The exact mechan-
ism of hypoalbuminemia predisposing to PD failure is
unclear. Potential mechanisms include predisposition to
peritonitis10 or relation to an underlying inflammatory
state.11 Not surprisingly, in our study, statistically significant
inverse correlation was noted between serum albumin and
CRP levels (Spearman’s r¼0.25, Po0.01).
Unavoidably, this study has some limitations. A few
unavoidable caveats were inherent to its case–control design.
We attempted to minimize selection bias by selecting all
consecutive patients commencing de novo on PD and
recruiting a randomly matched group, which is believed to
be similar to the PKD group with respect to various
comorbidities and inflammatory profile. Indeed, we con-
firmed that the case controls (randomly selected from a pool
potential cases that were matched for age, gender, and year of
commencement of PD) had similar demographics, biochem-
ical, and dialysis indices. Moreover, both groups also had
similar kidney transplantation rates. It is possible that good
PD outcome for PKD patients was a result of careful
selection. However, the majority of PKD patients were
established on PD and the transplant rate for the PKD
patients on HD was higher than those established on PD,
thereby suggesting that it is extremely unlikely that healthier
patients were selected for PD therapy.
The strengths of our study include relatively large size and
long follow-up. Indeed, the minimal effect size or minimal
detectable difference, which this sample size has 80% power
to assess, is 0.48. In addition, the demographic characteristics
of our patient population, including patients from various
ethnicities, support the generalizability of our findings to
PKD patients on PD elsewhere.
In conclusion, we observed no difference in long-term
outcome of PD therapy in PKD patients compared with a
nondiabetic matched control group. Further prospective
studies are required to confirm this observation.
MATERIALS AND METHODS
Patients
We identified from our electronic database incident PKD patients
starting dialysis between 1 January 1994 and 31 December 2005.
Each PKD patient established on PD was matched with a
nondiabetic patient with bilateral small kidneys of the same age,
gender, and year of attaining ESRF. If there were more than one
potential match, the case control was selected randomly.
Clinical data and laboratory investigations
Clinical data including comorbidity, details of transplantation, and
peritonitis data were collected from our regularly updated detailed
computerized records and review of patient medical and nursing
notes. Comorbid conditions collected included history of angina,
previous myocardial infarction within the past 3 months, previous
myocardial infarction more than 3 months ago, cerebrovascular
disease (including intracranial hemorrhage), diabetes (not causing
established renal failure), chronic obstructive pulmonary disease,
malignancy (excluding basal cell carcinoma), claudication, smoking
(current or history of smoking with in the previous year), and
angioplasty/stenting/vascular grafts (all noncoronary). Presence of
each disease was assigned a score of 1 and Davies comorbidity
score12 was calculated. Data related to extra-renal complications of
PKD were specifically collected, including occurrence of bilateral
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nephrectomy, hernia surgeries, valvular heart disease, leaks, bowel
perforation secondary to diverticular disease, and intracranial
hemorrhage secondary to ruptured vascular aneurysm.
Relevant biochemical data collected included baseline hemoglo-
bin, albumin, cholesterol, phosphates, and serum CRP levels. Serum
CRP concentrations were analyzed by the immunoturbimetric
method (Olympus Diagnostics, Hamburg, Germany). An elevated
CRP was defined as X5 mg/l that is the upper limit in the general
population. Albumin concentration was determined by the
bromocresol green method (Olympus AU640; Olympus Diagnos-
tics). Cholesterol and phosphates were determined by cholesterol
esterase method and phosphomolybdate method, respectively
(Olympus AU640; Olympus Diagnostics).
Dialysis dose (Kt/V) was calculated from 24-h dialysate
collection using computer software (Adequacy, Baxter Healthcare).
Peritoneal membrane transport and dialysate-to-plasma ratios of
creatinine at 4 h (D:Pcr) was calculated from PET13 and residual
renal function was measured from standardized 24-h urine
collection (calculated as mean of urea and creatinine clearance
and expressed normalized to 1.73 m2 body surface area). All patients
were dialyzed using conventional lactate-buffered glucose-based PD
solutions. Estimated glomerular filtration rates were calculated
according to Modification of Diet in Renal Disease formula14 using
equation 186.3 serum creatinine1.154 age0.203 0.742 (if
female patient) 1.212 (if black).
Definitions of outcome variables
The diagnosis of peritonitis was based on at least two of the
following criteria: abdominal pain or cloudy PD effluent, leucocy-
tosis in peritoneal fluid effluent (white blood cell count at least 100
per mm3), or Gram-positive stain or culture from effluent. Our
empiric antibiotic and treatment protocol has been previously
published.15 Death within 30 days of switching on to HD was
considered death on PD, with the assumption that deaths occurring
during this short period were likely to be associated with PD.
Permanent cessation of PD due to PD-related complications was
defined as technique failure.
Statistical analysis
Results are expressed as mean±s.d. for continuous data and as
percentages for categorical data. The significance of differences in
clinical and laboratory data between the groups was tested by
unpaired t-test, Mann–Whitney U-test, Wilcoxon signed-rank test,
and w2-test as appropriate. Survival curves were constructed
according to Kaplan–Meier method, and comparisons between
survival curves were made with the use of the logrank test. To
identify risk factors for technique survival in PKD patients on PD,
survival analysis was performed using Cox regression analysis with
the use of backward conditional stepwise elimination method
(SPSS software version 12). Data were censored at the time of
kidney transplantation, death, or 31 December 2005 for death-
censored technique survival. All statistical analyses were two
sided, and P-values less than 0.05 were considered statistical
significance.
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